Correlation Engine 2.0
Clear Search sequence regions


  • control groups (2)
  • delirium (9)
  • humans (1)
  • patients (8)
  • ramelteon (6)
  • Sizes of these terms reflect their relevance to your search.

    There is no clear evidence on the prevention of postoperative delirium with pharmacotherapy in elderly patients with esophageal cancer. This retrospective study aimed to evaluate the efficacy of ramelteon and suvorexant in preventing postoperative delirium in this patient group. Data on 251 patients who received radical esophagectomy for thoracic esophageal cancer were collected from January 2010 to September 2021. In total, 74 patients did not receive preventive intervention, and 177 received ramelteon and suvorexant. After propensity score matching, the rate of postoperative delirium was compared between the two groups. Seventy-two well-balanced patients in each group demonstrated similar clinical and pathological characteristics. The mean ages of the intervention and control groups were 70.8 and 70.3 years, respectively. All the patients underwent McKeown esophagectomy, and in the volume of intraoperative blood loss or operative time did not significantly differ between the two groups. The incidence rates of postoperative hyperactive delirium were 7% (5/72) in the intervention group and 32% (23/72) in the control group (p < 0.001). No severe adverse event potentially attributable to the intervention drug was observed. The multivariate analysis showed that the use of ramelteon and suvorexant was the only independent protective factor against postoperative delirium (hazard ratio 0.157, 95% CI 0.055-0.448, p < 0.001). Ramelteon and suvorexant may play an important role in reducing postoperative delirium in elderly patients with esophageal cancer. © 2023. The Author(s) under exclusive licence to The Japan Esophageal Society.

    Citation

    Shuhei Mayanagi, Ryoma Haneda, Masazumi Inoue, Kenjiro Ishii, Yasuhiro Tsubosa. Ramelteon and suvorexant for postoperative delirium in elderly patients with esophageal cancer. Esophagus : official journal of the Japan Esophageal Society. 2023 Oct;20(4):635-642

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 37561254

    View Full Text